


Amendments to the Claims:

This listing of claims replaces all prior versions, and listings, of claims in the application:

Listing of Claims:

1 to 7. (canceled)

8. (currently amended) A pharmaceutical composition comprising a compound of Formula I according to claim 1



I

Wherein

m is 0, 1, 2 or 3;


n is 0 or 1;

–A–B–C–D– is selected from the group consisting of:

- (1) –CH₂–CH₂–CH₂–O–,
- (2) –CH₂–CH₂–C(O)–O–,
- (3) –CH=CH–C(O)–O–,
- (4) –O–CH₂–CH₂–CH₂–,
- (5) –O–C(O)–CH₂–CH₂–,
- (6) –HC=CH–CH₂–O–,
- (7) –CH₂–HC=CH–O–,
- (8) –CH₂–CH₂–C(O)–NH–,
- (9) –CH₂–NH–CH₂–CH₂–,

- (10) -CH₂-NH-C(O)-O-,
(11) -NH-C(O)-NH-C(O)-,
(12) -C(O)-NH-C(O)-NH-,
(13) -NH-C(O)-NH-CH₂-,
(14) -NH-C(O)-NH-C(=S)-,
(15) -O-CH₂-CH₂-O- and
(16) -S-CH₂-CH₂-S-;

provided that when the atoms at positions B and C of -A-B-C-D-
are both carbon atoms, said atoms may be joined together to form a ring selected from



R¹ is phenyl or pyridyl said phenyl or pyridyl optionally mono or di- substituted with a substituent independently selected from the group consisting of:

- (a) halo,
(b) OCH₃,
(d) CH₃,
(e) CN; and

R² and R³ are each individually hydrogen or methyl[.]; and

each R⁴ is independently selected from the group consisting of

- (1) -OH,
(2) -C₁₋₆alkyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, oxo, -COOH, amino, methylamino, di-methylamino, =S, and halo,
(3) C₂₋₆alkenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, halo and -C(O)-O- C₁₋₂alkyl,

(4) C₂₋₆alkynyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy and halo,

(5) phenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, C₁₋₂alkyl, -COOH, -C(O)-O-CH₃ and halo,

(6) -C₁₋₂alkyl-phenyl optionally substituted with 1, 2 or 3 substituents independently selected from hydroxy, C₁₋₂alkyl and halo,

(7) -CO₂H,

(8) -CO₂C₁₋₃alkyl,

(9) -OC₁₋₃alkyl,

(10) -SO₂-C₁₋₃alkyl,

(11) -SO₂-phenyl optionally substituted with 1, 2 or 3 substituents independently selected from hydroxy, C₁₋₂alkyl and halo

(12) -C₁₋₂alkyl-O-C₁₋₂alkyl,

(13) -C₁₋₂alkyl-O-C₂₋₄alkenyl,

(14) -C₁₋₂alkyl-O-phenyl optionally substituted with 1, 2 or 3 substituents independently selected from hydroxy, C₁₋₂alkyl and halo,

(15) -C₁₋₂alkyl-C(O)O-C₁₋₂alkyl,

(16) 2-(1,3-dioxan)ethyl,

(17) -C₁₋₂alkyl-C(O)-NH-phenyl and

(18) -C₁₋₂alkyl-C(O)-NHN;

in combination with a pharmaceutically acceptable carrier.

9. (currently amended) ~~A compound~~ The pharmaceutical composition according to claim 8 wherein

Each R⁴ is independently selected from the group consisting of

(1) -OH,

(2) -C₁₋₆alkyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, oxo, -COOH, amino, methylamino, di-methylamino, thio, and halo,

(3) C₂₋₆alkenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, halo and -C(O)-O- C₁₋₂alkyl,

- (4) phenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, C₁-2alkyl, -COOH, -C(O)-O-CH₃ and halo,
- (5) -C₁-2alkyl-phenyl optionally substituted with 1, 2 or 3 substituents independently selected from hydroxy, C₁-2alkyl and halo,
- (6) -SO₂-C₁-3alkyl, and
- (7) -C₁-2alkyl-OC₁-2alkyl.


10. (currently amended) ~~A compound~~ The pharmaceutical composition according to claim 9 wherein

-A-B-C-D- is selected from the group consisting of:

- (1) -CH₂-CH₂-CH₂-O-,
- (2) -CH=CH-CH₂-O-,
- (3) -CH₂-CH=CH-O-,
- (4) -O-CH₂-CH₂-CH₂-,
- (5) -O-CH₂-CH₂-O-,
- (6) -S-CH₂-CH₂-S-,
- (7) -CH₂-NH-CH₂-CH₂-, and
- (8) -CH₂-NH-C(O)-O-;

R¹ is phenyl optionally mono or di- substituted with halo.

11. (currently amended) A compound of Formula II ~~according to claim 1~~



II

Wherein

m is 0, 1 or 2;

n is 0 or 1;

X and Y are each independently selected from CH₂, S and O;

R¹ is phenyl or pyridyl said phenyl or pyridyl optionally mono or di- substituted with a substituent independently selected from the group consisting of:

- (a) halo,
- (b) OCH₃,
- (d) CH₃,
- (e) CN; and

R² and R³ are each individually hydrogen or methyl[.]; and

each R⁴ is independently selected from the group consisting of

- (1) -OH,
- (2) -C₁₋₆alkyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, oxo, -COOH, amino, methylamino, di-methylamino, =S, and halo,
- (3) C₂₋₆alkenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, halo and -C(O)-O- C₁₋₂alkyl,
- (4) C₂₋₆alkynyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy and halo,
- (5) phenyl optionally substituted with 1, 2 or 3 substituents selected independently from hydroxy, C₁₋₂alkyl, -COOH, -C(O)-O-CH₃ and halo,
- (6) -C₁₋₂alkyl-phenyl optionally substituted with 1, 2 or 3 substituents independently selected from hydroxy, C₁₋₂alkyl and halo,
- (7) -CO₂H,
- (8) -CO₂C₁₋₃alkyl,
- (9) -OC₁₋₃alkyl,
- (10) -SO₂-C₁₋₃alkyl,
- (11) -SO₂-phenyl optionally substituted with 1, 2 or 3 substituents independently selected from hydroxy, C₁₋₂alkyl and halo
- (12) -C₁₋₂alkyl-O-C₁₋₂alkyl,
- (13) -C₁₋₂alkyl-O-C₂₋₄alkenyl,
- (14) -C₁₋₂alkyl-O-phenyl optionally substituted with with 1, 2 or 3 substituents independently selected from hydroxy, C₁₋₂alkyl and halo,
- (15) -C₁₋₂alkyl-C(O)O-C₁₋₂alkyl,
- (16) 2-(1,3-dioxan)ethyl,

(17) -C₁₋₂alkyl-C(O)-NH-phenyl and


(18) -C₁₋₂alkyl-C(O)-NHN;


12. (currently amended) A compound according to claim 11 wherein
~~Within this genus, there is a sub-genus of compounds wherein~~
each R⁴ is independently selected from the group consisting of -C₁₋₆alkyl or hydrogen.


13. (original) A compound according to claim 11 wherein
X and Y are both O or are both S or X is O and Y is CH₂;
R¹ is phenyl optionally mono or di- substituted with halo.


14. (currently amended) A compound ~~according to claim 1~~ selected from one of
the ~~group~~ following groups: ~~consisting of~~


i)






















ii)



<u>K</u>	<u>R</u>
<u>1</u>	<u>Vinyl</u>
<u>1</u>	<u>Phenyl</u>
<u>1</u>	<u>4-fluorophenyl</u>
<u>2</u>	<u>Benzyl</u>
<u>2</u>	<u>Vinyl</u>
<u>2</u>	<u>Ethyl</u>


iii)





<u>k</u>	<u>D</u>	<u>A</u>	<u>C</u>	<u>Ra</u>	<u>Rb</u>
<u>1</u>	<u>O</u>	<u>CH₂</u>	<u>CH₂</u>	<u>propyl</u>	<u>Propyl</u>
<u>1</u>	<u>O</u>	<u>CH₂</u>	<u>CHOH</u>	<u>propyl</u>	<u>Propyl</u>
<u>1</u>	<u>O</u>	<u>CH₂</u>	<u>CH₂</u>	<u>allyl</u>	<u>Allyl</u>
<u>1</u>	<u>O</u>	<u>CH₂</u>	<u>CHOH</u>	<u>allyl</u>	<u>Allyl</u>
<u>1</u>	<u>O</u>	<u>CH₂</u>	<u>CH₂</u>	<u>methyl</u>	<u>Methyl</u>
<u>1</u>	<u>O</u>	<u>CH₂</u>	<u>CHOH</u>	<u>methyl</u>	<u>Methyl</u>
<u>1</u>	<u>O</u>	<u>CH₂</u>	<u>C(O)</u>	<u>methyl</u>	<u>Methyl</u>
<u>1</u>	<u>O</u>	<u>CH₂</u>	<u>CH₂</u>	<u>H</u>	<u>H</u>
<u>1</u>	<u>O</u>	<u>CH₂</u>	<u>CHOH</u>	<u>H</u>	<u>H</u>
<u>2</u>	<u>CH₂</u>	<u>O</u>	<u>CH₂</u>	<u>ethyl</u>	<u>H</u>
<u>2</u>	<u>CH₂</u>	<u>O</u>	<u>CH₂</u>	<u>H</u>	<u>Ethyl</u>
<u>2</u>	<u>CH₂</u>	<u>O</u>	<u>CH₂</u>	<u>H</u>	<u>Phenyl</u>
<u>2</u>	<u>O</u>	<u>CH₂</u>	<u>CH(allyl)</u>	<u>allyl</u>	<u>Allyl</u>
<u>2</u>	<u>O</u>	<u>CH₂</u>	<u>CH₂</u>	<u>methyl</u>	<u>Methyl</u>
<u>2</u>	<u>O</u>	<u>CH₂</u>	<u>CH₂</u>	<u>benzyl</u>	<u>Benzyl</u>
<u>2</u>	<u>O</u>	<u>CH₂</u>	<u>CH₂</u>	<u>allyl</u>	<u>Allyl</u>
<u>2</u>	<u>O</u>	<u>CH₂</u>	<u>CHOH</u>	<u>methyl</u>	<u>Methyl</u>
<u>2</u>	<u>O</u>	<u>CH₂</u>	<u>CHOH</u>	<u>allyl</u>	<u>Allyl</u>
<u>2</u>	<u>O</u>	<u>CH₂</u>	<u>CH(allyl)</u>	<u>H</u>	<u>H</u>
<u>2</u>	<u>O</u>	<u>CH₂</u>	<u>C(O)</u>	<u>methyl</u>	<u>Methyl</u>

<u>2</u>	<u>O</u>	<u>CH₂</u>	<u>C(O)</u>	<u>allyl</u>	<u>Allyl</u>
----------	----------	-----------------------	-------------	--------------	--------------




iv)











Serial No.: 10/551,933
Case No.: 21150P
Page 19
















v)




<u>k</u>	<u>R</u>
<u>1</u>	<u>phenyl</u>
<u>2</u>	<u>ethyl</u>
<u>2</u>	<u>phenyl</u>

vi)



<u>Ra</u>
<u>Methyl</u>
<u>Allyl</u>
<u>Isopropyl</u>
<u>2-methoxyethyl</u>
<u>CH₂CO₂Et</u>
<u>2-(1,3-dioxan)ethyl</u>


vii)





<u>C₁</u>	<u>D₁</u>	<u>A₁</u>	<u>B₁</u>
<u>C(O)</u>	<u>NCH₃</u>	<u>C(O)</u>	<u>NH</u>
<u>NCH₂Ph</u>	<u>C(O)</u>	<u>NCH₃</u>	<u>C(O)</u>
<u>NCH₃</u>	<u>C(O)</u>	<u>NCH₃</u>	<u>C(O)</u>
<u>NCH₂CH=C</u> <u>H₂</u>	<u>C(O)</u>	<u>NCH₃</u>	<u>C(O)</u>
<u>C(O)</u>	<u>NCH₃</u>	<u>C(O)</u>	<u>NCH₂Ph</u>
<u>C(O)</u>	<u>NCH₃</u>	<u>C(O)</u>	<u>NCH₃</u>
<u>C(O)</u>	<u>NCH₃</u>	<u>C(O)</u>	<u>NCH₂CH=C</u> <u>H₂</u>
<u>C(O)</u>	<u>NCH₃</u>	<u>C(O)</u>	<u>NH</u>
<u>N(CH₂)₂CO₂</u> <u>H</u>	<u>C(O)</u>	<u>NCH₂Ph</u>	<u>C(O)</u>
<u>NH</u>	<u>C(O)</u>	<u>N(CH₂)₂CO₂</u> <u>H</u>	<u>C(O)</u>
<u>NH</u>	<u>C(O)</u>	<u>N(CH₂)₂</u> 	<u>C(O)</u>
<u>C(O)</u>	<u>NCH₃</u>	<u>C(O)</u>	<u>N(CH₂)₂CO₂</u> <u>H</u>
<u>C(O)</u>	<u>NCH₃</u>	<u>C(O)</u>	<u>N(CH₂)₂</u>
<u>NCH₂CH=C</u>	<u>C(O)</u>	<u>NCH₂CH=C</u>	<u>C(O)</u>


<u>H₂</u>		<u>H₂</u>	
<u>NCH₂Ph</u>	<u>C(O)</u>	<u>NCH₂Ph</u>	<u>C(O)</u>
<u>NH</u>	<u>C(S)</u>	<u>NCH₂Ph</u>	<u>C(O)</u>
<u>NH</u>	<u>C(S)</u>	<u>NH</u>	<u>C(O)</u>
<u>NH</u>	<u>C(S)</u>	<u>NCH₂CH=C</u>	<u>C(O)</u>
		<u>H₂</u>	
<u>NH</u>	<u>C(S)</u>	<u>NCH₃</u>	<u>C(O)</u>
<u>NH</u>	<u>CH₂</u>	<u>NCH₂Ph</u>	<u>C(O)</u>
<u>NH</u>	<u>CH₂</u>	<u>NH</u>	<u>C(O)</u>
<u>C(O)</u>	<u>NCH₃</u>	<u>CH₂</u>	<u>NCH₃</u>
<u>NH</u>	<u>CH₂</u>	<u>NCH₃</u>	<u>C(O)</u>


viii)

























Serial No.: 10/551,933
Case No.: 21150P
Page 35


















































Serial No.: 10/551,933
Case No.: 21150P
Page 52










or a pharmaceutically acceptable salt of any of the foregoing compounds.

15 to 21. (canceled)

22. (currently amended) A pharmaceutical composition comprising a compound according to claim [[1]] 11 in combination with a pharmaceutically acceptable carrier.

23 to 27. (canceled)

28. (new) The pharmaceutical composition according to Claim 8 wherein the compound of Formula I is



29. (new) The pharmaceutical composition according to Claim 28 wherein the compound of Formula I is

